Evolus Inc (EOLS) - Net Assets
Based on the latest financial reports, Evolus Inc (EOLS) has net assets worth $-28.76 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($219.00 Million) and total liabilities ($247.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Evolus Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-28.76 Million |
| % of Total Assets | -13.13% |
| Annual Growth Rate | -8.26% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 76.88 |
Evolus Inc - Net Assets Trend (2015–2024)
This chart illustrates how Evolus Inc's net assets have evolved over time, based on quarterly financial data. Also explore Evolus Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Evolus Inc (2015–2024)
The table below shows the annual net assets of Evolus Inc from 2015 to 2024. For live valuation and market cap data, see Evolus Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $5.52 Million | +126.69% |
| 2023-12-31 | $-20.69 Million | -211.84% |
| 2022-12-31 | $18.50 Million | -77.41% |
| 2021-12-31 | $81.88 Million | +212.22% |
| 2020-12-31 | $-72.96 Million | -191.82% |
| 2019-12-31 | $79.46 Million | -5.84% |
| 2018-12-31 | $84.38 Million | +211.70% |
| 2017-12-31 | $-75.54 Million | -963.09% |
| 2016-12-31 | $-7.11 Million | -159.21% |
| 2015-12-31 | $12.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Evolus Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 56265800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.02% |
| Other Comprehensive Income | $-905.00K | -16.39% |
| Other Components | $615.83 Million | 11152.21% |
| Total Equity | $5.52 Million | 100.00% |
Evolus Inc Competitors by Market Cap
The table below lists competitors of Evolus Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Site Centers Corp
NYSE:SITC
|
$291.69 Million |
|
Aspen Aerogels Inc
NYSE:ASPN
|
$291.74 Million |
|
Bank Of India Indonesia Tbk
JK:BSWD
|
$291.81 Million |
|
Promotora Ambiental S.A.B. de C.V
MX:PASAB
|
$291.82 Million |
|
Orrön Energy AB (publ)
ST:ORRON
|
$291.68 Million |
|
Global Partner Acquisition II Corp
NASDAQ:GPAC
|
$291.60 Million |
|
Tong-Tai Machine Tool Co Ltd
TW:4526
|
$291.57 Million |
|
Cogstate Ltd
AU:CGS
|
$291.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Evolus Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -20,689,000 to 5,522,000, a change of 26,211,000.
- Net loss of 50,420,000 reduced equity.
- New share issuances of 51,211,000 increased equity.
- Other comprehensive income decreased equity by 478,000.
- Other factors increased equity by 25,898,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-50.42 Million | -913.07% |
| Share Issuances | $51.21 Million | +927.4% |
| Other Comprehensive Income | $-478.00K | -8.66% |
| Other Changes | $25.90 Million | +469.0% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Evolus Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 59.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 8.26x to 59.86x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.65 | $5.33 | x |
| 2016-12-31 | $-0.38 | $5.33 | x |
| 2017-12-31 | $-3.20 | $5.33 | x |
| 2018-12-31 | $-5.04 | $5.33 | x |
| 2019-12-31 | $2.81 | $5.33 | x |
| 2020-12-31 | $-2.16 | $5.33 | x |
| 2021-12-31 | $1.64 | $5.33 | x |
| 2022-12-31 | $0.33 | $5.33 | x |
| 2023-12-31 | $-0.36 | $5.33 | x |
| 2024-12-31 | $0.09 | $5.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Evolus Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -913.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.94%
- • Asset Turnover: 1.14x
- • Equity Multiplier: 42.12x
- Recent ROE (-913.07%) is below the historical average (-174.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -259.22% | 0.00% | 0.00x | 6.77x | $-32.31 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.35 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $3.07 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-34.56 Million |
| 2019 | -113.31% | -257.79% | 0.15x | 3.03x | $-97.98 Million |
| 2020 | 0.00% | -288.31% | 0.27x | 0.00x | $-155.72 Million |
| 2021 | -57.17% | -46.96% | 0.39x | 3.14x | $-55.00 Million |
| 2022 | -402.25% | -50.07% | 0.84x | 9.62x | $-76.26 Million |
| 2023 | 0.00% | -30.52% | 1.07x | 0.00x | $-59.62 Million |
| 2024 | -913.07% | -18.94% | 1.14x | 42.12x | $-50.97 Million |
Industry Comparison
This section compares Evolus Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $459,373,250
- Average return on equity (ROE) among peers: -63.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Evolus Inc (EOLS) | $-28.76 Million | -259.22% | N/A | $291.69 Million |
| Aurora Cannabis Inc (ACB) | $605.09 Million | 0.26% | 0.40x | $197.35 Million |
| Akanda Corp (AKAN) | $26.90 Million | -43.34% | 0.45x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $1.82 Billion | 13.28% | 0.39x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $164.76 Million | -183.14% | 0.18x | $1.77 Billion |
| Amphastar P (AMPH) | $337.33 Million | 1.34% | 0.35x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $15.92 Million | -75.48% | 0.12x | $1.80 Billion |
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels.… Read more